Home> Products> Inhibitors> Masitinib mesylate-CAS 1048007-93-7
price inquiry for CAS:1048007-93-7, Product:Masitinib mesylate
For research use only. We do not sell to patients.

Masitinib mesylate CAS: 1048007-93-7

Category: Inhibitors
Product Name: Masitinib mesylate
Cat No: I000269
CAS No: 1048007-93-7
Synonyms: N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate
Molecular Formula: C29H34N6O4S2
Molecular Weight: 594.75
SMILES: CC1=C(NC2=NC(C3=CN=CC=C3)=CS2)C=C(NC(C4=CC=C(CN5CCN(C)CC5)C=C4)=O)C=C1.CS(=O)(O)=O
Solubility: 10 mM in DMSO
Target: PDGFR
IC50: 200 nM (Kit); 540 nM/800 nM(PDGFRα/β) [1]
Storage: Store at -20°C
CAS 1048007-93-7,Masitinib mesylate
  • Description

Masitinib(AB-1010) mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
IC50 value: 200 nM (Kit); 540 nM/800 nM(PDGFRα/β) [1]
Target: c-Kit; PDGFRα/β
in vitro: In Ba/F3 cells expressing human wild-type Kit, Masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC50 of 150 nM, while the IC50 for inhibition of IL-3-stimulated proliferation is at approximately >10 μM. In Ba/F3 cells expressing PDGFRα, Masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC50 of 300 nM. Masitinib also causes inhibition of SCF-stimulated tyrosine phosphorylation of human Kit in mastocytoma cell-lines and BMMC. Masitinib inhibits Kit gain-of-function mutants, including V559D mutant and Δ27 mouse mutant with IC50 of 3 and 5 nM in Ba/F3 cells. Masitinib inhibits the cell proliferation of mastocytoma cell lines including HMC-1α155 and FMA3 with IC50 of 10 and 30 nM, respectively [1]. Masitinib inhibits cell growth and PDGFR phosphorylation in two novel ISS cell lines, which suggest that Masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS [2].
in vivo: Masitinib inhibits tumour growth and increases the median survival time in Δ27-expressing Ba/F3 tumor models at 30 mg/kg, without cardiotoxicity or genotoxicity [1]. Masitinib (12.5 mg/kg/d PO) increases overall TTP (time-to-tumor progression) compared with placebo in dogs [3].

  • References


[1]. Dubreuil P, et al. Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT. PLoS One, 2009, 4(9), e7258.
[2]. Lawrence J, et al. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Vet Comp Oncol, 2011, doi: 10.1111/j.1476-5829.2011.00291.x.
[3]. Hahn KA, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med, 2008, 22(6), 1301-1309.


price inquiry for CAS:1048007-93-7, Product:Masitinib mesylate